Additional file 1 of The opposing effect of acute and chronic Toxoplasma gondii infection on tumor development
Creators: name: Song, Yining
name: Yuan, Hao
name: Yang, Xiaoying
name: Yang, Zipeng
name: Ren, Zhaowen
name: Qi, Shuting
name: He, Houjing
name: Zhang, Xiu-Xiang
name: Jiang, Tiantian
name: Yuan, Zi-Guo
Publisher: name: figshare
Year: 2024
Subjects: subject: Immunology
subject: FOS: Clinical medicine

description: Additional file 1: Figure S1. Significance analysis of luminescence intensity from bioluminescence imaging of live mice injected with LLC-Luc cells (model III). (a) Data of LLC, LLC + Pru and Pru (acute) + LLC were recorded every other day from day 1 to day 27 post-LLC injection. (b) Data of LLC and Pru (chronic) + LLC were recorded every other day from day 1 to day 27 post-LLC injection. Data are means ± SD (*P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001). Figure S2. The effect of T. gondii acute infection on T cells in peripheral blood (model III). (a) On day 15 after the mice were injected LLC cells, CD3+ T cells in peripheral blood accounted for the proportion of total cells; CD4+ T cells as a percentage of CD3+ T cells; CD8+ T cells as a percentage of CD3-T cells; Th1 CD4+ T cells as a percentage of CD4+ T cells; and Granzyme B as a percentage of CD8+ T cells. (b) On day 15 after the mice were injected with LLC cells, CD4+ T cells in peripheral blood accounted for the proportion of total cells; CD8+ T cells accounted for the proportion of total cells. (c) On day 15 after the mice were injected with LLC cells, Th1+ CD4+ T cells in peripheral blood accounted for the proportion of total cells; and Granzyme B accounted for the proportion of total cells. (d) On day 25 after the mice were injected with LLC cells, CD3+ T cells in peripheral blood accounted for the proportion of total cells; CD4+ T cells as a percentage of CD3+ T cells; CD8+ T cells as a percentage of CD3− T cells; Th1 CD4+ T cells as a percentage of CD4+ T cells; Granzyme B as a percentage of CD8+ T cells. (e) On day 25 after the mice were injected with LLC cells, CD4+ T cells in peripheral blood accounted for the proportion of total cells; CD8+ T cells accounted for the proportion of total cells. (f) On day 25 after the mice were injected with LLC cells, Th1 CD4+ T cells accounted for the proportion of total cells; and Granzyme B accounted for the proportion of total cells. Data are means ± SD (**P &lt; 0.01, ***P &lt; 0.001). Figure S3. The percentages of on effector T cells in peripheral blood (model III). (a) On day 15 after the mice were injected LLC cells, CD3+ T cells in peripheral blood accounted for the proportion of total cells; CD4+ T cells as a percentage of CD3+ T cells; CD8+ T cells as a percentage of CD3-T cells; Th1 CD4+ T cells as a percentage of CD4+ T cells; Granzyme B as a percentage of CD8+ T cells. (b) On day 15 after the mice were injected with LLC cells, CD4+ T cells in peripheral blood accounted for the proportion of total cells; CD8+ T cells accounted for the proportion of total cells. (c) On day 15 after the mice were injected with LLC cells, Th1 CD4+ T cells in peripheral blood accounted for the proportion of total cells; and Granzyme B accounted for the proportion of total cells. (d) On day 25 after the mice were injected with LLC cells, CD3+ T cells in peripheral blood accounted for the proportion of total cells; CD4+ T cells as a percentage of CD3+ T cells; CD8+ T cells as a percentage of CD3− T cells; Th1 CD4+ T cells as a percentage of CD4+ T cells; Granzyme B as a percentage of CD8+ T cells. (e) On day 25 after the mice were injected with LLC cells, CD4+ T cells in peripheral blood accounted for the proportion of total cells; CD8+ T cells accounted for the proportion of total cells. (f) On day 25 after the mice were injected with LLC cells, Th1 CD4+ T cells accounted for the proportion of total cells; and Granzyme B accounted for the proportion of total cells. Data are means ± SD (*P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001). Figure S4. Tumor images were captured from three C57BL/6J mice 15 days and 25 days post-injection of LLC-Luc cells.(a) Acute infection of T. gondii inhibits tumor growth (model II). (b) Chronic infection of T. gondii promotes tumor growth (model II). Figure S5. Luminescence intensity pictures from bioluminescence imaging of live mice injected with LLC-Luc cells. (a) Bioluminescent imaging of tumor progression in LLC, LLC + Pru, and Pru (acute) + LLC groups. (b) Bioluminescent imaging of tumor progression in LLC and Pru (chronic) + LLC groups. Table S1. Quantitative real-time PCR specific primers set (model II). Table S2. Four-week tumor formation rates in KM mice and BALB/c mice (model III).